Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | HMGCR | P04035 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095222 | 1.00 | FFAR1 (0.40) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5092667 | 0.88 | FFAR1 (0.48) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5092657 | 0.88 | FFAR1 (0.48) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5092664 | 0.85 | GRM5 (0.40) | FFAR1FFAR4KCNH2TLR8 | |
| SCHEMBL5092655 | 0.85 | GRM5 (0.40) | FFAR1FFAR4KCNH2TLR8 | |
| SCHEMBL5095343 | 0.83 | FFAR1 (0.44) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5095348 | 0.83 | FFAR1 (0.44) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5092719 | 0.81 | TSHR (0.46) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5092713 | 0.81 | TSHR (0.46) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL3940735 | 0.80 | FFAR1 (0.43) | FFAR1FFAR4MMP2MMP12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332623-B2 | Aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-02-19 | — | — | US | disclosed |
| US-20050004212-A1 | Aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY | 2005-01-06 | — | — | US | disclosed |
| US-20050004211-A1 | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004211-A1 | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds | CCNI, TOP1, TOP2B | FFAR1 1438/4885FFAR4 3707/4885MMP2 667/4885 |
| US-20050004212-A1 | Aryl-substituted acyclic enediyne compounds | CCNI, TOP2B, TOP2A | FFAR1 1803/4885FFAR4 3818/4885MMP2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.